- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02862704
A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)
August 8, 2016 updated by: Xijing Hospital
An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Safety and Efficacy of Intratumoral Delivery Mediated MG7-targeted Chimeric Antigen Receptor T Cells in Advanced MG7 Positive Liver Metastases
The purpose of this study is to collect the data on the safety and potential effectiveness of intra-tumor injection of MG7-CART cells under ultrasound guidance in patients with liver metastases expressing MG7 positively.
Study Overview
Detailed Description
Designer T cells are prepared by PBMC which from patients by leukapheresis, and then activated and re-engineered to express chimeric antigen receptors (CARs) specific for MG7, which is a glycosylated protein of CEA.
Cells are expanded in culture and returned to the participant by intra-tumor injection at the dose of (1-6)×108 CAR positive T cells.
The cells perfusion process would last for 1min to 2min.
The dose of 1.5 grams/m2 of cyclophosphamide will be given two days before CART cell infusion.
Study Type
Interventional
Enrollment (Anticipated)
20
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yongzhan Nie, Doctor
- Email: yongznie@fmmu.edu.cn
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 701032
- Recruiting
- Xijing Hospital of Digestive Diseases
-
Contact:
- Yongzhan Nie, Doctor
- Email: yongznie@fmmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 69 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- MG7 expression positive by histologically confirmed;
- Aged between 18 and 69;
- Persistent cancer after at least one prior standard of care chemotherapy, has no willing for surgery or cannot be suitable for surgery patients;
- Tumor is too big to surgical resection;
- Life expectancy greater than 4 months;
- Satisfactory organ and bone marrow function as defined by the following: (1) creatinine <1.5mg/dl; (2) cardiac ejection fraction of >55%; (3) hemoglobin>9g/dl, bilirubin 2.0×the institution normal upper limit;
- Without bleeding disorder or coagulation disorders;
- Dont allergy to Radiocontrast agent;
- Birth control;
- Adequate venous access for apheresis, and no other contraindications for leukapheresis;
- Voluntary informed consent is given.
Exclusion Criteria:
- Pregnant or lactating women;
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary;
- Patients in the situation of: (1) 30 days before apheresis is still in the period of other antitumor drug observation; (2) patient dont recuperate from earlier acute adverse influence brought by any treatments accepted before;
- Four weeks before recruit accepted radiation therapy;
- Previously treatment with any gene therapy products;
- Feasibility assessment during screening demonstrates<30% transduction of target lymphocytes, or insufficient expansion (<5-fold) in response to CD3/CD28 costimulation;
- Any serious, uncontrolled diseases (including, but not limit to, unstable angina pectoris, congestive heart failure, grade III or IV cardiac disease, serious arrhythmia, liver and kidney disorders or metabolic diseases, CNS diseases);
- Patient with severe acute hypersensitive reaction;
- Taking part in other clinical trials;
- Study leader considers not suitable for this tiral.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MG7-CART
A single dose of MG7-CART cells will be administered by intra-tumor injection under ultrasound guidance.
The dose is 1-6x108 MG7-CAR positive T cells.
The infusion will be scheduled to occur 2 days after two doses of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures.
The cells perfusion process would lasts 1min to 2min, and an interventional radiologist would operate the cell infusion.
|
Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects.
And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with adverse event
Time Frame: 6 weeks
|
adverse event is evaluated with CTCAE, version 4.0
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of patients with tumor response
Time Frame: 8 weeks
|
summarize tumor response by overal response rates
|
8 weeks
|
Detection of transferred T cells in the circulation using quantitative -PCR
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Yongzhan Nie, Doctor, Xijing Hospital of Digestive Diseases
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2016
Primary Completion (Anticipated)
May 1, 2017
Study Completion (Anticipated)
December 1, 2017
Study Registration Dates
First Submitted
August 7, 2016
First Submitted That Met QC Criteria
August 8, 2016
First Posted (Estimate)
August 11, 2016
Study Record Updates
Last Update Posted (Estimate)
August 11, 2016
Last Update Submitted That Met QC Criteria
August 8, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MG7-CART
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Metastases
-
Society of Interventional OncologyRecruitingColorectal Liver MetastasesUnited States, Netherlands, Greece
-
Memorial Sloan Kettering Cancer CenterCompletedLocalize Liver MetastasesUnited States
-
Heidelberg UniversityUnknownColorectal Liver MetastasesGermany
-
Dr. M.R. MeijerinkAmsterdam UMC, location VUmcCompletedColorectal Liver Metastases | Metastatic Liver DiseaseNetherlands
-
University of ZurichCompletedColorectal Liver MetastasesSwitzerland, France, Spain
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingUnresectable Colorectal Liver MetastasesFrance
-
Peking University Cancer Hospital & InstituteRecruitingColorectal Liver MetastasesChina
-
Amsterdam UMC, location VUmcCompletedColorectal Liver MetastasesNetherlands
-
David BartlettNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedColorectal Liver MetastasesUnited States
-
University of MilanCompleted
Clinical Trials on MG7-CART
-
University of PennsylvaniaNovartisActive, not recruitingMultiple MyelomaUnited States
-
University of Southern CaliforniaCompleted
-
Chinese University of Hong KongNot yet recruiting
-
Shanghai Unicar-Therapy Bio-medicine Technology...RecruitingAcute Myeloid LeukemiaChina
-
Shanghai Simnova Biotechnology Co.,Ltd.Active, not recruitingMultiple MyelomaChina
-
University of PennsylvaniaTerminatedLYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)United States
-
Laboratoires ArkopharmaCompleted
-
Fujian Medical UniversityUnknown
-
University of Sao PauloHospital das Clínicas de Ribeirão Preto; Blood Center of Ribeirao PretoNot yet recruitingLymphoma, Non-Hodgkin | Leukemia, Acute LymphoblasticBrazil
-
University of PennsylvaniaCompletedAdult Patients Who Have Relapsed or Refractory CLL (3rd Line) or SLLUnited States